Last reviewed · How we verify
Entecavir + Pegylated interferon α-2b
This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and pegylated interferon α-2b to enhance immune response against HBV-infected cells.
This combination uses entecavir to inhibit hepatitis B virus reverse transcriptase and pegylated interferon α-2b to enhance immune response against HBV-infected cells. Used for Chronic hepatitis B infection.
At a glance
| Generic name | Entecavir + Pegylated interferon α-2b |
|---|---|
| Also known as | Runzhong®, PEGBING® |
| Sponsor | Qing-Lei Zeng |
| Drug class | Antiviral combination (nucleoside reverse transcriptase inhibitor + immunomodulator) |
| Target | HBV reverse transcriptase; interferon-α receptor |
| Modality | Small molecule |
| Therapeutic area | Virology/Hepatology |
| Phase | FDA-approved |
Mechanism of action
Entecavir is a nucleoside reverse transcriptase inhibitor that directly blocks HBV replication by inhibiting the viral polymerase enzyme. Pegylated interferon α-2b is an immunomodulator that enhances innate and adaptive immune responses to clear HBV-infected hepatocytes. The combination aims to achieve superior viral suppression and potentially higher rates of HBeAg seroconversion compared to monotherapy.
Approved indications
- Chronic hepatitis B infection
Common side effects
- Flu-like symptoms (fever, fatigue, myalgia)
- Neutropenia
- Thrombocytopenia
- Depression/psychiatric effects
- Headache
- Injection site reactions
- Lactic acidosis (entecavir-related)
Key clinical trials
- Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B (PHASE4)
- Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B (PHASE4)
- Real-world Study Evaluating the Long-term Outcomes of Pegylated Interferon α-2b Treatment in the Families With Clusters of HBV Infection and Unfavorable Prognosis - A Prospective, Controlled, Multicenter, Cohort Study
- Pegylated Interferon α in Previously Interferon-treated CHB（Leading Study） (NA)
- Antiviral Therapy for Patients With Liver Cancer After Surgery
- Combination Treatment of NAs and Peg IFN α-2b for Hepatitis B Related, Compensatory Cirrhosis Patients (PHASE2)
- Pegylated Interferon Alpha-2b Monotherapy Versus Combination With Entecavir in HBeAg-negative Chronic Hepatitis B (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Entecavir + Pegylated interferon α-2b CI brief — competitive landscape report
- Entecavir + Pegylated interferon α-2b updates RSS · CI watch RSS
- Qing-Lei Zeng portfolio CI